Cargando…

Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy

INTRODUCTION: Sjögren's syndrome (SjS) is a systemic autoimmune disease characterized by decreased salivary and lacrimal gland secretions, resulting in severe dry mouth and dry eyes. Recent studies have suggested that T(H)17 cells and its signature cytokine IL-17 are involved in the underlying...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Byung Ha, Carcamo, Wendy C, Chiorini, John A, Peck, Ammon B, Nguyen, Cuong Q
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580566/
https://www.ncbi.nlm.nih.gov/pubmed/22827855
http://dx.doi.org/10.1186/ar3925
_version_ 1782260278201679872
author Lee, Byung Ha
Carcamo, Wendy C
Chiorini, John A
Peck, Ammon B
Nguyen, Cuong Q
author_facet Lee, Byung Ha
Carcamo, Wendy C
Chiorini, John A
Peck, Ammon B
Nguyen, Cuong Q
author_sort Lee, Byung Ha
collection PubMed
description INTRODUCTION: Sjögren's syndrome (SjS) is a systemic autoimmune disease characterized by decreased salivary and lacrimal gland secretions, resulting in severe dry mouth and dry eyes. Recent studies have suggested that T(H)17 cells and its signature cytokine IL-17 are involved in the underlying pathogenic mechanisms leading to destructive inflammation and autoimmunity. In the present study, we examined whether IL-27, a natural inhibitor of T(H)17 activity, could down-regulate or reverse SjS in C57BL/6.NOD-Aec1Aec2 mice, a model of primary-SjS. METHODS: Recombinant serotype 2 adeno-associated viral (AAV2) vectors expressing either IL-27 (rAAV2-IL27) or LacZ (rAAV2-LacZ) were injected into 6 or 14 week-old C57BL/6.NOD-Aec1Aec2 mice. Changes in IL-27, IL-17, and IL-10 cytokine levels in peripheral blood were determined by ELISAs, while flow cytometry analyses were used to quantify cytokine-positive splenocytes. Histological assessment of salivary glands, anti-nuclear autoantibody (ANA) staining, and stimulated saliva flow rates were used to profile SjS disease severity. RESULTS: Mice systemically treated with intravenous rAAV2-IL27 injections at either 6 or 14 weeks of age exhibited long-term elevated levels of serum IL-27 with concomitantly reduced levels of IL-17 compared with sera from mice injected with rAAV2-LacZ or saline out to 20 weeks post-inoculation. Most importantly, disease profiles revealed that rAAV2-IL27 treatment had little effect on lymphocytic focus (LF) scores, but resulted in structural changes in LF, lower titers of ANAs with changes in staining patterns, and a less severe clinical disease as determined by saliva flow rates. CONCLUSIONS: These data support the concept that IL-27, when provided exogenously, can induce a suppressive effect on SjS development and thus may be an effective therapeutic agent for regulating T(H)17 pro-inflammatory activity in autoimmune diseases where the T(H)17 system has been shown to play an important role in their pathogenesis.
format Online
Article
Text
id pubmed-3580566
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35805662013-02-26 Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy Lee, Byung Ha Carcamo, Wendy C Chiorini, John A Peck, Ammon B Nguyen, Cuong Q Arthritis Res Ther Research Article INTRODUCTION: Sjögren's syndrome (SjS) is a systemic autoimmune disease characterized by decreased salivary and lacrimal gland secretions, resulting in severe dry mouth and dry eyes. Recent studies have suggested that T(H)17 cells and its signature cytokine IL-17 are involved in the underlying pathogenic mechanisms leading to destructive inflammation and autoimmunity. In the present study, we examined whether IL-27, a natural inhibitor of T(H)17 activity, could down-regulate or reverse SjS in C57BL/6.NOD-Aec1Aec2 mice, a model of primary-SjS. METHODS: Recombinant serotype 2 adeno-associated viral (AAV2) vectors expressing either IL-27 (rAAV2-IL27) or LacZ (rAAV2-LacZ) were injected into 6 or 14 week-old C57BL/6.NOD-Aec1Aec2 mice. Changes in IL-27, IL-17, and IL-10 cytokine levels in peripheral blood were determined by ELISAs, while flow cytometry analyses were used to quantify cytokine-positive splenocytes. Histological assessment of salivary glands, anti-nuclear autoantibody (ANA) staining, and stimulated saliva flow rates were used to profile SjS disease severity. RESULTS: Mice systemically treated with intravenous rAAV2-IL27 injections at either 6 or 14 weeks of age exhibited long-term elevated levels of serum IL-27 with concomitantly reduced levels of IL-17 compared with sera from mice injected with rAAV2-LacZ or saline out to 20 weeks post-inoculation. Most importantly, disease profiles revealed that rAAV2-IL27 treatment had little effect on lymphocytic focus (LF) scores, but resulted in structural changes in LF, lower titers of ANAs with changes in staining patterns, and a less severe clinical disease as determined by saliva flow rates. CONCLUSIONS: These data support the concept that IL-27, when provided exogenously, can induce a suppressive effect on SjS development and thus may be an effective therapeutic agent for regulating T(H)17 pro-inflammatory activity in autoimmune diseases where the T(H)17 system has been shown to play an important role in their pathogenesis. BioMed Central 2012 2012-07-24 /pmc/articles/PMC3580566/ /pubmed/22827855 http://dx.doi.org/10.1186/ar3925 Text en Copyright ©2012 Lee et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lee, Byung Ha
Carcamo, Wendy C
Chiorini, John A
Peck, Ammon B
Nguyen, Cuong Q
Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
title Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
title_full Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
title_fullStr Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
title_full_unstemmed Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
title_short Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
title_sort gene therapy using il-27 ameliorates sjögren's syndrome-like autoimmune exocrinopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580566/
https://www.ncbi.nlm.nih.gov/pubmed/22827855
http://dx.doi.org/10.1186/ar3925
work_keys_str_mv AT leebyungha genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy
AT carcamowendyc genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy
AT chiorinijohna genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy
AT peckammonb genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy
AT nguyencuongq genetherapyusingil27amelioratessjogrenssyndromelikeautoimmuneexocrinopathy